Gilteritinib maintenance therapy for FLT3-ITD mutated acute myeloid leukaemia

Gilteritinib is in clinical development as maintenance therapy for patients with FMS-like tyrosine kinase 3 internal tandem duplication (FLT3-ITD) acute myeloid leukaemia (AML) who have received a haematopoietic stem cell transplant (HSCT) and are in first complete remission (CR1). AML is a type of cancer of the white blood cells which are important in fighting infections and controlling tissue damage. HSCT aims to cure AML, but the disease often comes back. FLT3-ITD mutations in AML are common and are associated with a poor prognosis. Maintenance treatments continue after the patient is in remission following HSCT to stop any remaining cancerous cells from spreading and surviving. The aim of maintenance treatment is to increase relapse-free and overall survival times. There are currently no recommended treatment options for maintenance treatment in patients with FLT3-ITD AML who have undergone HSCT.